Gastrointestinal Cancer

Andreas Kaubisch, MD, discusses the phase III REACH and REACH-2 trials in advanced hepatocellular carcinoma.

Allyson Ocean, MD, discusses the use of circulating tumor DNA in pancreatic cancer.

Manish A. Shah, MD, discusses biomarkers in gastric and gastroesophageal junction cancer.

In a phase III trial, investigators are examining if arfolitixorin can supplant leucovorin calcium, a widely used component of combination regimens in patients with metastatic colorectal cancer.

Richard Kim, MD, discusses treatment options for BRAF-mutant colon cancer.

Manuel Hidalgo Medina, MD, PhD, discusses the emergence of neoadjuvant chemotherapy and radiation in pancreatic cancer.

Nonalcoholic fatty liver disease, a risk factor linked to the development of hepatocellular carcinoma and increased mortality, is growing in clinical significance.

Allyson Ocean, MD, discusses efforts to improve early detection rates in pancreatic cancer.

Cathy Eng, MD, FACP, FASCO, discusses unique barriers facing patients with early-onset colorectal cancer.

Varlitinib combined with capecitabine did not improve progression-free survival nor overall response rate compared with capecitabine/placebo as a second-line treatment in patients with biliary tract cancer.

The FDA has granted a priority review designation to a supplemental biologics license application for the combination of nivolumab and ipilimumab for the treatment of patients with advanced hepatocellular carcinoma who received prior therapy with sorafenib.

Andreas Kaubisch, MD, sheds light on systemic therapies available in liver cancer and some of the practice-changing phase III trials that have read out in the space.

Avelumab did not improve overall survival as frontline maintenance following induction chemotherapy in patients with unresectable, locally advanced, or metastatic HER2-negative gastric or gastroesophageal junction cancer.

Allyson Ocean, MD, discusses pivotal trials in early pancreatic cancer, the need for genetic testing, and other research efforts focused on improving patient outcomes.

Lakshmi N. Rajdev, MD, an associate professor, Department of Medicine (Oncology), at Albert Einstein College of Medicine, Montefiore Medical Center, discusses the difference between cancers and carcinomas in neuroendocrine tumors (NETs).

Ryan B. Corcoran, MD, PhD, discusses emerging therapeutics for patients with relapsed/refractory colorectal cancer.

The investigational agent pegvorhyaluronidase alfa in combination with gemcitabine and nab-paclitaxel did not show an improvement in overall survival compared with gemcitabine and nab-paclitaxel alone in patients with metastatic pancreatic cancer, missing the primary endpoint of the phase III HALO-109-301 trial.

Lukas E. Dow, PhD, discusses ongoing research evaluating Wnt as a potential target in colorectal cancer.

Al B. Benson, MD, discusses personalized treatment strategies for patients with metastatic colorectal cancer.

Manish A. Shah, MD, discusses ongoing research evaluating immunotherapy and other novel treatments in advanced gastric and gastroesophageal junction cancer.

Andreas Kaubisch, MD, discusses available treatment options for hepatocellular carcinoma.

Al B. Benson, MD, discusses key considerations in the frontline treatment of patients with metastatic colorectal cancer.

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

Overall, compelling response rates and rates of conversion to resection for patients with initially unresectable colorectal liver metastases treated with hepatic arterial infusion suggest consideration of earlier initiation of the technique in chemotherapy-naïve patients as well as its adoption in patients who have failed first-line systemic chemotherapy before proceeding to second- or third-line regimens.

Ghassan K. Abou-Alfa, MD, discusses the results of the phase III ClarIDHy trial in advanced cholangiocarcinoma.